Abstract
Background: Infectious control measures during the COVID-19 pandemic have led to the propensity toward telemedicine. This study examined the impact of telemedicine during the pandemic on the long-term outcomes of ST-segment elevation myocardial infarction (STEMI) patients. Methods: This study included 288 patients admitted 1 year before the pandemic (October 2018-December 2018) and during the pandemic (January 2020-March 2020) eras, and survived their index STEMI admission. The follow-up period was 1 year. One-year primary safety endpoint was all-cause mortality. Secondary safety endpoints were cardiac readmissions for unplanned revascularisation, non-fatal myocardial infarction, heart failure, arrythmia, unstable angina. Major adverse cardiovascular events (MACE) was defined as the composite outcome of each individual safety endpoint. Results: Despite unfavorable in-hospital outcomes among patients admitted during the pandemic compared to pre-pandemic era, both groups had similar 1-year all-cause mortality (11.2 vs. 8.5%, respectively, p = 0.454) but higher cardiac-related (14.1 vs. 5.1%, p < 0.001) and heart failure readmissions in the pandemic vs. pre-pandemic groups (7.1 vs. 1.7%, p = 0.037). Follow-up was more frequently conducted via teleconsultations (1.2 vs. 0.2 per patient/year, p = 0.001), with reduction in physical consultations (2.1 vs. 2.6 per patient/year, p = 0.043), during the pandemic vs. pre-pandemic era. Majority achieved guideline-directed medical therapy (GDMT) during pandemic vs. pre-pandemic era (75.9 vs. 61.6%, p = 0.010). Multivariable Cox regression demonstrated achieving medication target doses (HR 0.387, 95% CI 0.164-0.915, p = 0.031) and GDMT (HR 0.271, 95% CI 0.134-0.548, p < 0.001) were independent predictors of lower 1-year MACE after adjustment. Conclusion: The pandemic has led to the wider application of teleconsultation, with increased adherence to GDMT, enhanced medication target dosing. Achieving GDMT was associated with favorable long-term prognosis.
Introduction
The COVID-19 pandemic necessitated a rapid transformation in healthcare delivery. For survivors of ST-segment elevation myocardial infarction (STEMI)—the most serious type of heart attack—consistent follow-up is critical for optimizing recovery and preventing secondary events. Traditionally, this care involves frequent in-person visits for clinical assessment and medication titration. However, pandemic-related lockdowns and fears of hospital exposure led to significant delays in emergency presentations and disruptions to routine physical consultations. This study investigates whether the forced pivot to telemedicine compromised patient safety or if it provided a viable alternative for maintaining high-quality post-STEMI care.
Methods
This retrospective, single-center observational study was conducted at the National University Heart Centre, Singapore. Researchers compared two cohorts of STEMI survivors: a pre-pandemic group (n=118, admitted Oct–Dec 2018) and a pandemic group (n=170, admitted Jan–Mar 2020). Patients were followed for one year post-discharge.
Data were extracted from the Hospital STEMI Registry and Electronic Medical Records, including the frequency of teleconsultations versus physical visits, medication dosages, and laboratory results (e.g., LDL cholesterol). The primary endpoint was one-year all-cause mortality. Secondary endpoints included Major Adverse Cardiovascular Events (MACE), encompassing readmissions for heart failure, recurrent myocardial infarction, and unstable angina. Multivariable Cox regression was used to adjust for confounders such as age and heart function (LVEF).
Results
Shift in Care Delivery
The pandemic era saw a significant shift in how follow-up care was delivered. Teleconsultations increased from 0.2 to 1.2 per patient/year (p = 0.001), while physical consultations decreased from 2.6 to 2.1 per patient/year (p = 0.043).
Clinical Outcomes and Medication Adherence
Patients admitted during the pandemic presented with more severe initial clinical markers, including higher rates of sepsis and lower LVEF. Despite this, one-year all-cause mortality was comparable between the two groups (11.2% pandemic vs. 8.5% pre-pandemic, p = 0.454). However, the pandemic group experienced higher rates of heart failure readmissions (7.1% vs. 1.7%, p = 0.037), likely reflecting the increased severity of their index events.
Notably, adherence to Guideline-Directed Medical Therapy (GDMT) was significantly higher in the pandemic group (75.9% vs. 61.6%, p = 0.010). Achievement of target doses for beta-blockers and ACE inhibitors/ARBs also trended higher.
Multivariable analysis identified GDMT achievement as a powerful independent predictor of lower MACE (HR 0.271, p < 0.001), suggesting that improved medication management effectively mitigated the risks associated with more severe initial presentations.
Discussion
These findings suggest that telemedicine served as a "synergistic extension" of care rather than a mere replacement. The increased frequency of teleconsultations likely provided more opportunities for clinicians to titrate medications to target doses, which is a cornerstone of post-STEMI management. The study reinforces that the clinical content of the visit—specifically the delivery of GDMT—is more critical for long-term outcomes than the physical presence of the patient, provided that monitoring can be conducted effectively.
Conclusion
The COVID-19 pandemic accelerated the adoption of telemedicine in post-STEMI care. This shift was associated with improved adherence to GDMT and comparable one-year survival rates, despite more severe initial presentations during the pandemic. Future efforts should focus on standardizing hybrid care models that leverage the strengths of both physical and tele-consultations to optimize patient outcomes.
Summary updated